RFK Jr., The FDA, and the Future of Peptides: What Could Change for BPC-157, TB-500, CJC-1295 and More
The Peptide EffectShow Notes
In this episode we explore the growing conversation around Robert F. Kennedy Jr. and the possibility of several peptides being reconsidered within the FDA regulatory system. Many peptides that were once available through compounding pharmacies were restricted in recent years, leaving physicians and patients without access through traditional medical channels.
We break down the peptides frequently discussed in these regulatory conversations, including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, Thymosin Alpha-1, Epitalon, KPV, LL-37, Kisspeptin-10, Melanotan II, Dihexa, and Mechano Growth Factor. We talk about what these peptides do, why they were restricted, and what potential regulatory changes could mean for the future of peptide therapy.
This episode also dives into the larger discussion about innovation, patient access, compounding pharmacies, and the evolving role of peptides in regenerative medicine, longevity science, metabolic health, and recovery.
Whether you are new to peptides or have been following the regulatory landscape for years, this episode gives you a clear overview of what is being discussed, what could change, and why it matters.
More from The Peptide Effect
CBL-514 is making waves in fat-reduction research, but despite showing up in peptide conversations, it isn’t a peptide. In this episode of The Peptide Effect, we explain what it is, how it differs from AOD-9604, and how peptides like tesamorelin, semaglutide, tirzepatide, and retatrutide fit into the discussion. Discover the differences between targeted fat reduction, visceral fat reduction, and overall weight loss—and what the research actually supports.
What if GLP-1 drugs are doing more than controlling blood sugar and reducing appetite? In this episode of The Peptide Effect, we break down a 2026 study revealing a newly identified molecular “switch” involving Med14, a protein that helps regulate gene transcription inside pancreatic beta cells. Researchers found that sustained GLP-1 receptor signaling may activate broader gene programs tied to beta-cell function, metabolism, and viability. We’ll explain what Med14 is, what phosphorylation means, how GLP-1 signals travel from the cell surface to the nucleus, and why this discovery could matter for the future of metabolic medicine. We’ll also separate what the study actually found from the exaggerated claims you may see online, including whether GLP-1 drugs permanently “reprogram” the pancreas. A fascinating look at what may be happening beneath the surface of GLP-1 therapy, far beyond appetite suppression and weight loss.
Can we really unlock the body’s natural limits on muscle growth? In this episode of The Peptide Effect, we explore the science behind peptide-based myostatin inhibitors and why they’ve become one of the most talked-about areas of peptide research. Learn what myostatin is, how it regulates muscle growth, the differences between compounds like follistatin, ACE-031, apitegromab, and bimagrumab, and why researchers are investigating these therapies for muscle-wasting diseases, aging, and athletic performance. We also separate scientific evidence from internet hype and discuss the potential benefits, limitations, and safety considerations surrounding this exciting field of research. Whether you’re interested in peptides, fitness, longevity, or the future of regenerative medicine, this episode provides an easy-to-understand overview of one of the most fascinating topics in modern biomedical research.
In this episode of The Peptide Effect, we explore the emerging world of apolipoprotein-targeting peptides and how they’re reshaping the future of cardiovascular and neurological research. Learn how apolipoproteins transport cholesterol throughout the body, why HDL function may be just as important as HDL levels, and how experimental peptides such as 4F, 5A, ATI-5261, FAMP, CN-105, and D6PV are being investigated for their potential to improve cholesterol metabolism, reduce inflammation, protect the brain, and support healthy aging. We’ll also discuss reverse cholesterol transport, ApoA-I, ApoE, ApoC-II, and the role these peptides may play in the future of precision medicine. Whether you’re interested in peptide science, longevity, heart health, or cutting-edge biomedical research, this episode offers a comprehensive introduction to one of the newest frontiers in peptide therapeutics.
In this episode, we break down the recent surge in peptide seizures at U.S. borders and what it really means for availability, pricing, and the future of the peptide market. From supply chain disruptions and rising costs to shifts in sourcing, quality, and regulation, you’ll get a clear, no-nonsense look at what’s driving these changes. Whether you’re a consumer, researcher, or building a brand in the space, this episode helps you understand what’s happening now and how to navigate what’s coming next.